5-MeO-MALT, also known as 5-methoxy-N-methyl-N-allyltryptamine, is a psychedelic drug of the tryptamine family related to 5-MeO-DALT.
5-MeO-MALT was first described in the literature in 2004. It was encountered as a novel designer drug in 2014. The drug's pharmacology was studied and described in greater detail in 2024.
5-MeO-MALT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved).
The pharmacology of 5-MeO-MALT has been studied. It is a potent serotonin 5-HT<sub>2A</sub> receptor agonist and produces the head-twitch response in rodents. The drug also shows high affinity for the serotonin 5-HT<sub>1A</sub> receptor.
Analogues of 5-MeO-MALT include methylallyltryptamine (MALT), 4-HO-MALT (maltocin), 4-AcO-MALT, 5-MeO-DMT, 5-MeO-DET, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MET, 5-MeO-MPT, 5-MeO-MiPT, 5-MeO-EiPT, and 5-MeO-iPALT (ASR-3001), among others.
5-MeO-MALT is not a controlled substance in Canada as of 2025.
5-MeO-MALT is illegal in Hungary.
Sweden's public health agency suggested classifying 5-MeO-MALT as a hazardous substance, on May 15, 2019.
5-MeO-MALT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.